Wyeth shareholders have endorsed a proposal calling on the company to recoup bonuses and incentives from executives who are later found not to have met their performance goals. The vote was announced during the company's annual meeting. During the gathering, CEO Robert Essner also told stockholders that 2006 was a milestone year for the company with revenue passing $20 billion as sales of new biotech products like Enbrel have surged. The company also announced this morning that CFO and Vice Chairman Kenneth J. Martin plans to leave the company by the end of June to pursue personal interests.

- see the release on Martin's departure
- and here's the report on Wyeth from Newsday

ALSO: Sweden's Meda has acquired 10 established drug products in Europe from Wyeth. Release